In this study, the possible application of a panel enzyme immunoassay (EIA ) to the Epstein-Barr virus (EBV) infection was evaluated. The presence of antibodies reacting EBC recombinant antigen was assayed in the sera of suspected EBV infection
(45
cases) and healthy adult control (30 cases) groups. The panel EIA(Biotest AG, Dreieich, Germany) will detect three kinds of antibodies against the EBV antigen (EA) consisted of p54 and p138, which will react with IgM antibody and IgG antibody
separately. And the antigen component of Epstein-Barr nuclear antigen(EBNA) will detect the IgG class antibody circulating in the seta of test subjects. The test results from panel EIA test was compared with those of anti-EBV viral capsid antigen
(VCA)
IgM antibody test(BioWhittacker, Inc., M.D, U.S.A.) in the same specimens. In patient group, 10 cases922%0 were in the category of primary infection, 5 cases(11%) were considered acute reactivation, 22 cases(49%) were previous infection and 8
cases(18%)
showed negative test results. In normal control group, 25 cases (83%) were considered as having previous infection and in 5 cases(17%) were regarded as acute reactivation. In summary, we assume that the panel EIA test for antibodies to EBV using
recombinant antigens is useful for serodiagnosis of all the stages of EBV infections and more specific for the interpreting results than the conventional EIA test using EBV-VCA antigens in clinically suspected patients.
|